Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
Adolescents
Children
Infants
Omnitrope®
Pediatric
Recombinant human growth hormone
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
09
10
2019
accepted:
08
06
2020
pubmed:
20
6
2020
medline:
12
10
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin biosimilar Omnitrope PATRO Children is an ongoing, multicenter, observational, post-marketing surveillance study. Children who received Omnitrope A total of 291 patients (mean age 10.0 years, 56.0% male) were enrolled at 19 sites in Italy. The mean duration of Omnitrope In this sub-analysis of PATRO Children, Omnitrope
Identifiants
pubmed: 32557273
doi: 10.1007/s40618-020-01331-4
pii: 10.1007/s40618-020-01331-4
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-503Références
Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen J, Cianfarani S, Clayton P, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger D, Erfurth EM, Fuqua JS, Grimberg A, Haymond M, Higham C, Ho K, Hoffman AR, Hokken-Koelega A, Johannsson G, Juul A, Kopchick J, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger C, Swerdlow A, Thorner M (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 174(2):1–9. https://doi.org/10.1530/EJE-15-0873
doi: 10.1530/EJE-15-0873
Cook DM, Rose SR (2012) A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 15(3):301–310. https://doi.org/10.1007/s11102-011-0372-6
doi: 10.1007/s11102-011-0372-6
pubmed: 22271255
Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 86(6):361–397. https://doi.org/10.1159/000452150
doi: 10.1159/000452150
pubmed: 27884013
European Medicines Agency (2017) Omnitrope
López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J (2011) Long-term safety and efficacy of the recombinant human growth hormone Omnitrope
doi: 10.1007/s12325-011-0063-8
pubmed: 21948492
Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, Berghout A (2009) Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope
doi: 10.1159/000249164
pubmed: 19844125
Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S (2013) Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope
doi: 10.1177/2042018813479644
pubmed: 23515245
pmcid: 3593298
Pfaffle R, Kanumakala S, Hoybye C et al (2015) Results up to January 2015 from PATRO Children, a multi-centre, noninterventional study of the long-term safety and efficacy of Omnitrope
Pfäffle R, Kanumakala S, Hoybye C et al (2016) Four-year results from PATRO Children, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope
Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L, Bona G, Zecchino C, Aversa T, Persani L, Guazzarotti L, Zecchi E, Pietropoli A, Zucchini S (2016) Long-term safety and efficacy of Omnitrope
doi: 10.1186/s13052-016-0302-3
pubmed: 27809913
pmcid: 5096288
Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, Gilli G, Bona G, Fabris C, De Curtis M, Milani S (2010) Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 51(3):353–361. https://doi.org/10.1097/MPG.0b013e3181da213e
doi: 10.1097/MPG.0b013e3181da213e
pubmed: 20601901
Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51(3):170–179
doi: 10.1136/adc.51.3.170
Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355(9204):610–613. https://doi.org/10.1016/S0140-6736(99)04055-6
doi: 10.1016/S0140-6736(99)04055-6
pubmed: 10696981
Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A, Saenger P (2010) Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. Eur J Endocrinol 162(6):1051–1058. https://doi.org/10.1530/eje-09-1101
doi: 10.1530/eje-09-1101
pubmed: 20332125
Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak M, Wasik R, Ginalska-Malinowska M, Solyom E, Berghout A (2007) Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 30(7):578–589
doi: 10.1007/BF03346352
Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB (2006) Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 91(6):2047–2054. https://doi.org/10.1210/jc.2005-2284
doi: 10.1210/jc.2005-2284
pubmed: 16537676